Participants 39 118 6
previously treated patients with refractory advanced non-small-cell lung cancer
Participants 374 445 6
patients with locally advanced or metastatic non-small-cell lung cancer
Participants 455 542 8
1692 patients who were refractory to or intolerant of their latest chemotherapy regimen
Participants 942 995 5
1129 patients were assigned gefitinib and 563 placebo
Participants 1236 1268 4
812 patients with adenocarcinoma
Participants 1440 1460 3
never-smokers (n=375
Participants 1528 1559 3
patients of Asian origin (n=342
Participants 1929 1971 3
never-smokers and patients of Asian origin
